Table 1.
Illustrative listing of clinical trials examining combination immunotherapy and definitive radiation for LA-HNSCC.
| Trial | Ref | Phase | Study Design | Study Eligibility | Primary Outcome | Status | Estimated Completion |
|---|---|---|---|---|---|---|---|
| NCT02586207 | Powell JCO 2020 | IB | Pembro (200mg d-7) → CRT → RAA + Pembro (200mg x5) | LA-HNSCC (Stage III-IVB) | Safety/Tolerability | Active, Not Reruiting | Sep-23 |
| NCT02952586 | Lee Lancet 2021 | III | Avelumab (10mg/kg x1, d-7) → Avelumab (10mg/kg q2wk) + CRT → RAA + Avelumab (10mg/kg q2wk) | LA-HNSCC | PFS | Discontinued | Aug-20 |
| NCT03383094 | n/a | III | Pembro (200mg q3wk x20) + RT | LA-HNSCC | PFS | Recruiting | Jun-24 |
| NCT03258554 | n/a | II/III | Durva (1500mg wk-2 x7) + RT | LA-HNSCC | DLT/PFS/OS | Recruiting | Dec-25 |
| NCT02707588 | Bourhis AnnOnc 2020 | II | Pembro (200mg q3wk) + RT | LA-HNSCC | LRC | Active, Not Reruiting | Dec-21 |
| NCT03952585 | n/a | II/III | Reduced-Dose RT + Cisplatin vs Nivo (d-7 q2wk x6) | LA-HNSCC | PFS/QOL | Recruiting | Feb-25 |